Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test

... the results of clinical studies that support the company's Heart Health Genetic Test to assess cardiovascular risk. The article, titled, "IL1B Gene promoter Haplotype Pairs Predict Clinical Levels of Interleukin-1beta and C-reactive Protein," was published in the journal Human Genetics (123:387-398; May ...

Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma

... of primary brain cancer and carries a very poor prognosis with current therapy. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII that can be expressed by GBM. In the ACTIVATE Phase 2a study, GBM patients treated with CDX-110 showed a median survival time of 30 ...

Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme

... Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN ) in October 2007. In the ...

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

... England, to humanize Lpathomab to create a lead antibody for pre- clinical development. LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types, as well as a significant contributor to neuropathic pain. "Humanizing our ...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

... mutant gene delivered via a less-targeted viral promoter driven expression system ... C-VISA-BikDD. They used a gene-based targeting promoter called CCKAR known to be active in pancreatic ... after delivery. A system using a viral promoter such as CMV has the opposite problem: strong ...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

... of 8.1 months. In a defined patient subgroup with the methylated MGMT gene promoter in the tumor tissue, 91% of patients had six months PFS and the median has ... 54% 6 months PFS, median PFS of 6.9 months;(1) methylated MGMT gene promoter subgroup: 69% PFS and 10.3 months median PFS].(2) Lead investigator ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51

... inhibitors of DNA methyltransferase (DNMT). DNMT1 is considered to be the DNA methyltransferase enzyme mainly responsible for maintaining abnormal promoter methylation in various cancer types. Zebrafish embryos are a viable model for cancer drug research because of their close similarity to humans and ...

Telomerase Presentations at the AACR 2007 Annual Meeting

... of telomere loss prior to telomerase activation in various tumor types, the role of telomere dysfunction in tumorigenesis, and use of the telomerase promoter to drive tumor cell death. "The data presented at AACR contribute to the growing body of evidence regarding the importance of telomerase targeted ...

Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug Candidate, Sphingomab

... Lpathomab(TM), is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types. Lpath's unique ability to generate antibodies against bioactive lipids is ...